Sign in
WithdrawnPhase 2

The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients with ACC- an Open, Non-commercial Clinical Trial

Key facts

Who runs it
Maria Sklodowska-Curie National Research Institute of Oncology
Where
Poland1 site in 1 countryChoose a country to see its sites
Status
Withdrawn
Phase
Phase 2
Started
Jan 2024
Expected to end
Nov 2027
Type of study
Interventional
Treatments tested
  • Lutetium (177Lu) vipivotide tetraxetan
Record updated
10 February 2025
Why it stopped
Administrative reasons

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • Signing the informed consent form to participate in the study
  • Patients with inoperable, locoregionally advanced or metastatic, histopathologically confirmed adenoid cystic carcinoma of salivary gland
  • Age over 18 years
  • WHO performance status 0 to 2
  • PSMA expression confirmed by PET/CT using 68Ga-PSMA
  • Presence of measurable disease according to RECIST 1.1 criteria
  • Adequate function of: bone marrow, liver, kidneys:; bone marrow: neutrophils >1500x10\^9/L; thrombocytes >150,000x10\^9/L, hemoglobin >9 g/dl liver: bilirubin <2xULN; aminotransferases <3xULN (in patients with liver metastases <5xULN) kidney: eGFR >50 ml/min albumin >2.5 mg/ml
  • For women of reproductive age: confirmed negative pregnancy test
  • The need to use of a highly effective method of contraception

Who cannot take part

  • Concomitant treatment of another cancer
  • Previous treatment with 177Lutetium-labeled PSMA
  • Patients with metastases to the brain, meninges or heart
  • Severe or significant additional diseases in the opinion of the investigator
  • Lack of effective contraception during childbearing age
  • Pregnancy or breastfeeding
  • Urinary tract obstruction and/or hydronephrosis
  • Myelosuppressive or nuclear treatment later than 4 weeks after qualification

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Non-commercial phase 2 clinical trial to evaluate the effectiveness, safety and tolerability of treatment using prostate-specific membrane antigen (PSMA) labeled with 177Lutetium in patients with recurrence and/or metastases in adenoid cystic carcinoma originating from the salivary glands of the head and neck region.

Read full original descriptionShow less

Patients with PSMA receptor expression confirmed by PET/CT after administration of 68Ga-PSMA I\&T will be eligible for treatment.

The group in the trial

  • ExperimentalTreatment being tested

    Treatment will consist of administration of 6 cycles of lutetium (177Lu) vipivotide-tetraxetan with an activity of 200 mCi (7.4 GBq) at intervals of 6 weeks.

    Treatment: Lutetium (177Lu) vipivotide tetraxetan

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a Specialized Prostate-specific Membrane Antigen (PSMA) Labeled with Lutetium177, in Patients with Recurrent And/or Metastatic Adenoid Cystic Carcinoma Originating from the Salivary Glands - an Open, Non-commercial Clinical Trial
Record updated
10 February 2025